Albiglutide: A review of its use in patients with type 2 diabetes mellitus

Drugs

Volumn 75, Issue 6, 2015, Pages 651-663

  Blair, Hannah A ^a   Keating, Gillian M ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; RGLP-1 PROTEIN;

ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; HUMAN;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84939940582     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0370-5     Document Type: Review

References (57)

1. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37(Suppl. 1):S14-80.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-96.
3. Baggio LL, Huang Q, Brown TJ, et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53(9):2492-500.
4. Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009;11(5):498-505.
5. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig. 2013;4(2):108-30.
6. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126-31.
7. European Medicines Agency. Eperzan (albiglutide): summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 26 Feb 2015.
8. GlaxoSmithKline. Tanzeum (albiglutide): US prescribing information. 2014. http://www.accessdata.fda.gov. Accessed 26 Feb 2015.
9. Young MA, Wald JA, Matthews JE, et al. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgrad Med. 2014;126(7):84-97.
10. Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014;48(11):1494-501.
11. Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett. 2013;23(14):4011-8.
12. Hompesch M, Jones-Leone A, Carr MC, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2014.
13. Seino Y, Inagaki N, Miyahara H, et al. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014;30(6):1095-106.
14. Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32(10):1880-6.
15. Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009;25(12):3049-57.
16. European Medicines Agency. Eperzan assessment report. 2014. http://www.ema.europa.eu. Accessed 26 Feb 2015.
17. Rosenstock J, Stewart MW. Albiglutide. Drugs Future. 2010;35(9):701-12.
18. Darpo B, Zhou M, Matthews J, et al. Albiglutide does not prolong QTc interval in healthy subjects: a thorough ECG study. Diabetes Ther. 2014;5(1):141-53.
19. Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One. 2011;6(8):e23570.
20. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810-7.
21. Bush MA, Smith C, Watanalumlerd P, et al. Population pharmacokinetic (PK) analysis of albiglutide in a phase IIb study in japanese patients with type 2 diabetes [abstract no. 1020-P]. Diabetes. 2012;61(Suppl. 1):A261-2.
22. Bush M, Scott R, Watanalumlerd P, et al. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012;124(6):55-72.
23. Reusch J, Stewart MW, Perkins CM, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014;16(12):1257-64.
24. Reinhardt R, Nauck MA, Stewart M, et al. HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [abstract no. 903]. In: 49th Annual Meeting of the European Association for the Study of Diabetes; 2013.
25. Ahren B, Johnson SL, Stewart M, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-8.
26. Weissman PN, Carr MC, Ye J, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57(12):2475-84.
27. Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37(8):2317-25.
28. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289-97.
29. Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37(10):2723-30.
30. Home PD, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2014.
31. Carr MC, Rendell M, Scott RA, et al. Harmony 2 year 3 results: albiglutide monotherapy in drug naive patients with type 2 diabetes mellitus [abstract no. 830 plus poster]. In: 50th Annual Meeting of the European Association for the Study of Diabetes; 2014.
32. Martin AA, Johnson SL, Ye J. Treatment satisfaction with albiglutide and liraglutide in patients with type 2 diabetes uncontrolled with oral therapy [abstract no. 1010-P]. In: 73rd Annual Scientific Sessions of the American Diabetes Association; 2013.
33. Bode BW, Stewart M, Cirkel D, et al. Harmony 1 year 3 results: albiglutide vs. placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone (Pio) + metformin (Met) [abstract no. 960-P plus poster]. In: 74th Scientific Sessions of the American Diabetes Association; 2014.
34. Matthews JE, Ahren B, Ye J, et al. Harmony 3 year 3 results: albiglutide vs sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin [abstract no. 831 plus poster]. In: 50th Annual Meeting of the European Association for the Study of Diabetes; 2014.
35. Shamanna P, Home P, Stewart MW, et al. Harmony 5-year 3 results: albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes [abstract no. 838 plus poster]. In: 50th Annual Meeting of the European Association for the Study of Diabetes; 2014.
36. Weissman PN, Stewart MW, Cirkel DT, et al. Harmony 4: 3 year efficacy of albiglutide (ALBI) vs insulin glargine (GLAR) in patients with type 2 diabetes mellitus [abstract no. 837 plus poster]. In: 50th Annual Meeting of the European Association for the Study of Diabetes; 2014.
37. Martin AA, Johnson SL, Ye J, et al. Improved treatment satisfaction with weekly abiglutide vs. thrice daily prandial insulin added to insulin glargine in type 2 diabetes [abstract no. 2590-PO]. In: 73rd Scientific Sessions of the American Diabetes Association; 2013.
38. Fonseca VL, Ahren B, Chow F, et al. Once weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in type 2 diabetes: similar glycaemic control with weight loss and less hypoglycaemia [abstract no. 581]. In: 48th Annual Meeting of the European Association for the Study of Diabetes 2012.
39. Nino AJ, Davidson JA, Scott RA, et al. Albiglutide efficacy and safety in the African/African American subpopulation from the integrated phase III program [abstract no. 1003-P plus poster]. In: 74th Scientific Sessions of the American Diabetes Association; 2014.
40. Davidson JA, Jones-Leone A, Wilson TH, et al. Albiglutide efficacy and safety in the Hispanic/Latino subpopulation from the integrated phase III program [abstract no. 1004-P plus poster]. In: 74th Scientific Sessions of the American Diabetes Association; 2014.
41. Mallory JM, Leiter LA, Wilson TH, et al. Gastrointestinal safety across the albiglutide development program [abstract no. 1002-P plus poster]. Diabetes. 2014;63(Suppl. 1):A257-8.
42. Ambery PD, Donaldson J, Ye J, et al. Results of the albiglutide HARMONY program prospective major adverse cardiovascular event (MI, stroke, cardiovascular death, and unstable angina) meta-analysis [abstract no. 908 plus poster]. Diabetologia. 2014;57(Suppl. 1):S370.
43. Johnson S, Nauck MA, Zhi H, et al. Integrated phase 3 immunogenicity results for albiglutide [abstract no. 1640-P plus poster]. Diabetes. 2014;63(Suppl. 1):A427.
44. Ross SA, Dzida G, Vora J, et al. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin. 2011;27(7):1431-8.
45. Sisley S, Gutierrez-Aguilar R, Scott M, et al. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest. 2014;124(6):2456-63.
46. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-88.
47. Tzefos M, Harris K, Brackett A. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012;46(1):68-78.
48. Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S38-48.
49. Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121-31.
50. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care. 2013;36(Suppl 2):S245-52.
51. Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-9.
52. Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012;14(12):1123-8.
53. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370(9):794-7.
54. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245-54.
55. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5(5):475-7.
56. Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144-9.
57. Leiter LA, Scott RA, Ye J, et al. Medication compliance rates of weekly albiglutide vs. daily oral comparators in phase III trials [abstract no. 994-P plus poster]. In: 74th Scientific Sessions of the American Diabetes Association; 2014.